Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences

Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN) announced participation in two virtual investor conferences. The LifeSci Partners Corporate Access Event will be held from January 5-7, 2022, featuring 1x1 meetings. The second event, H.C. Wainwright BIOCNNECT Virtual Conference, is scheduled for January 10-13, 2022 with available on-demand presentations and 1x1 meetings. Eledon focuses on developing treatments for organ transplantation, autoimmune diseases, and neurodegenerative conditions, led by its compound AT-1501, targeting the CD40 ligand pathway.

IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that members of management will be participating in two upcoming virtual investor conferences:

Event:	LifeSci Partners Corporate Access Event (January 5-7, 2022)
Format:	1x1 Meetings

To register for the LifeSci Partners Corporate Access Event, please use the following link: here.

Event:	H.C. Wainwright BIOCNNECT Virtual Conference (January 10-13, 2022)
Format:	Available on Demand Presentation for registered attendees via the H.C. Wainwright site and 1x1 Meetings

If you are interested in arranging a one-on-one meeting request for the H.C. Wainwright BIOCNNECT Virtual Conference, please contact your H.C. Wainwright representative, or contact Corey Davis at the address below.

About Eledon Pharmaceuticals and AT-1501

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact
Corey Davis, Ph.D.         
LifeSci Advisors         
212-915-2577                 
cdavis@lifesciadvisors.com

FAQ

What events is Eledon Pharmaceuticals participating in January 2022?

Eledon Pharmaceuticals will participate in the LifeSci Partners Corporate Access Event from January 5-7, 2022, and the H.C. Wainwright BIOCNNECT Virtual Conference from January 10-13, 2022.

What is the format of the LifeSci Partners Corporate Access Event?

The format for the LifeSci Partners Corporate Access Event is 1x1 meetings.

What will be featured at the H.C. Wainwright BIOCNNECT Virtual Conference?

The H.C. Wainwright BIOCNNECT Virtual Conference will feature available on-demand presentations and 1x1 meetings for registered attendees.

What is AT-1501 developed by Eledon Pharmaceuticals?

AT-1501 is an anti-CD40L antibody developed by Eledon Pharmaceuticals, targeting the CD40 ligand pathway for potential treatments in organ transplantation and autoimmune diseases.

Where can I find more information about Eledon Pharmaceuticals?

More information about Eledon Pharmaceuticals can be found on their official website at www.eledon.com.